|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:Company
|
|
gptkbp:approves
|
gptkb:legislation
gptkb:2004
gptkb:United_States
|
|
gptkbp:average_temperature
|
2 to 8 degrees Celsius
|
|
gptkbp:brand
|
gptkb:Levemir
|
|
gptkbp:climax
|
6 to 8 hours
|
|
gptkbp:clinical_trial
|
Phase III
insulin therapy
blood glucose control
basal insulin therapy
|
|
gptkbp:contraindication
|
severe hypoglycemia
hypersensitivity to insulin detemir
|
|
gptkbp:dosage_form
|
injection
|
|
gptkbp:duration
|
long-acting
|
|
gptkbp:form
|
gptkb:software_framework
|
|
gptkbp:frequency
|
once or twice daily
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Levemir
|
|
gptkbp:indication
|
gptkb:Type_1_diabetes
Type 2 diabetes
|
|
gptkbp:ingredients
|
gptkb:insulin_detemir
C29 H46 N2 O5
|
|
gptkbp:interacts_with
|
gptkb:beer
gptkb:ACE_inhibitors
beta-blockers
other antidiabetic medications
thiazolidinediones
|
|
gptkbp:is_available_on
|
gptkb:tablet
vial
|
|
gptkbp:is_used_for
|
gptkb:Company
|
|
gptkbp:manager
|
gptkb:Company
subcutaneous
subcutaneous injection
syringe
|
|
gptkbp:manufacturer
|
gptkb:Novo_Nordisk
|
|
gptkbp:marketed_as
|
Levemir Flex Touch
Levemir Penfill
|
|
gptkbp:packaging
|
single-dose vial
multi-dose pen
|
|
gptkbp:pharmacokinetics
|
low variability in absorption
steady state reached after 2-3 days
|
|
gptkbp:population
|
gptkb:Person
adults
|
|
gptkbp:premiered_on
|
1 to 2 hours
|
|
gptkbp:regulatory_compliance
|
prescription only
|
|
gptkbp:related_to
|
gptkb:Company
gptkb:Novo_Nordisk
diabetes management
long-acting insulin
|
|
gptkbp:shelf_life
|
42 days after opening
|
|
gptkbp:side_effect
|
allergic reactions
weight gain
injection site reactions
hypoglycemia
|
|
gptkbp:type_of_care
|
important for efficacy
|
|
gptkbp:weight
|
518.69 g/mol
|